 "Chart Check: Aurobindo Pharma, Gallant Ispat, Lyka Labs, Asian Granito India")
Here are a few intra-day trading strategies from Geojit BNP Paribas for trade today:
AUROBINDO PHARMA
LTP: Rs 772.25
Action: SELL on rise
Targets: Rs 760 / Rs 745
Comment: Momentum indicators are signalling downtrend. MACD is about to cross the signal line from above. Volumes have jumped above the 10d average. Coming off the trendline resistance zone of Rs 865 levels. F&O segment is showing short built up.
GALLANT ISPAT
LTP: Rs 605.45
Action: BUY on dips
Targets: Rs 615 / Rs 635
Stop-loss: Rs 586
Comment: Momentum oscillators are supporting uptrend. Volumes have moved above the week's high.
LYKA LABS
LTP: Rs 86.85
Action: SELL on rise
Targets: Rs 85.2 / Rs 82.5
Stop-loss: Rs 90.5
Comment: Momentum oscillators are signalling profit booking. MACD is about to cross the signal line. The volumes have started to ease. Coming off the congestion zone of Rs 91.
ASIAN GRANITO INDIA
LTP: Rs 165.05
Action: BUY
Targets: Rs 168 / Rs 172
Stop-loss: Rs 161
Comment: RSI and Stochastics are supporting uptrend. MACD has crossed the signal line from above. Volumes have moved above the 10d average.
Disclaimer: This report has been prepared by Geojit BNP Paribas Financial Services Limited (GBNPP), here in after referred to as GBNPP. GBNPP, a publicly listed company, is engaged in services of retail broking, credit, portfolio management and marketing investment products including mutual funds, life and general insurance and properties. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this report (including the merits and risks involved). This document is not for public distribution and has been furnished to you solely for your information and must not be reproduced or redistributed to any other person. Persons into whose possession this document may come are required to observe these restrictions. Opinion expressed herein is our current opinion as of the date appearing on this report only. While we endeavor to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice.
AUROBINDO PHARMA
LTP: Rs 772.25
Action: SELL on rise
Targets: Rs 760 / Rs 745
More From This Section
Stop-loss: Rs 790
Comment: Momentum indicators are signalling downtrend. MACD is about to cross the signal line from above. Volumes have jumped above the 10d average. Coming off the trendline resistance zone of Rs 865 levels. F&O segment is showing short built up.
GALLANT ISPAT
LTP: Rs 605.45
Action: BUY on dips
Targets: Rs 615 / Rs 635
Stop-loss: Rs 586
Comment: Momentum oscillators are supporting uptrend. Volumes have moved above the week's high.
LYKA LABS
LTP: Rs 86.85
Action: SELL on rise
Targets: Rs 85.2 / Rs 82.5
Stop-loss: Rs 90.5
Comment: Momentum oscillators are signalling profit booking. MACD is about to cross the signal line. The volumes have started to ease. Coming off the congestion zone of Rs 91.
ASIAN GRANITO INDIA
LTP: Rs 165.05
Action: BUY
Targets: Rs 168 / Rs 172
Stop-loss: Rs 161
Comment: RSI and Stochastics are supporting uptrend. MACD has crossed the signal line from above. Volumes have moved above the 10d average.
Disclaimer: This report has been prepared by Geojit BNP Paribas Financial Services Limited (GBNPP), here in after referred to as GBNPP. GBNPP, a publicly listed company, is engaged in services of retail broking, credit, portfolio management and marketing investment products including mutual funds, life and general insurance and properties. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this report (including the merits and risks involved). This document is not for public distribution and has been furnished to you solely for your information and must not be reproduced or redistributed to any other person. Persons into whose possession this document may come are required to observe these restrictions. Opinion expressed herein is our current opinion as of the date appearing on this report only. While we endeavor to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice.